treatment

Building clinically relevant outcomes across the Alzheimer’s disease spectrum

Authors: Dorene M. Rentz, Alette M. Wessels, Ananth V. Annapragada, Anna‐Karin Berger, Chris J. Edgar, Michael Gold, David S. Miller, Christopher Randolph, J. Michael Ryan, Glen Wunderlich, Megan Canniere Zoschg, Dominic Trépel, David S. Knopman, Adam M. Staffaroni, Lisa J. Bain, Maria C. Carrillo, Christopher J. Weber

Journal: Alzheimer's & Dementia

Year Published: 2021

Demonstrating that treatments are clinically meaningful across the Alzheimer’s disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer’s Association Research […]

Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II

Authors: C H Chatham, K I Taylor, T Charman, X Liogier D'ardhuy, E Eule, A Fedele, A Y Hardan, E Loth, L Murtagh, M Del Valle Rubido, A San Jose Caceres, J Sevigny, L Sikich, L Snyder, J E Tillmann, P E Ventola, K L Walton-Bowen, P P Wang, T Willgoss, F Bolognani

Journal: Autism Research

Year Published: 2018

Abstract: Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive […]

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study

Authors: Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findling

Journal: Journal of Child and Adolescent Psychopharmacology

Year Published: 2017

Objective: To evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. Methods: Patients aged 13-17 years were randomly assigned to 6 weeks of double-blind, fixed-dose lurasidone (40 or 80 mg/day) or […]

Back to Publications